title: Development of the hepatitis E vaccine: from bench to field.
abstract: Along with the improvement of diagnostic techniques, hepatitis E has attracted increasing awareness in recent years. Hepatitis E virus infection leads to high mortality in pregnant women and patients with underlying liver disease. Several hepatitis E vaccine candidates have been designed and have proved their efficacy in animal models; two candidates have successfully undergone clinical trials. Having proved safe and effective in a large phase III trials, an Escherichia coli expressed particulate protein, HEV 239, has been registered in China and is now available for use in China.
authors.affiliation: National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, People's Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: James WaiKuo
authors.initials: JW
authors.lastname: Shih
authors.forename: Ting
authors.initials: T
authors.lastname: Wu
authors.forename: Shao-Wei
authors.initials: SW
authors.lastname: Li
authors.forename: Ning-Shao
authors.initials: NS
authors.lastname: Xia
mesh_terms: D002681:China; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational; D016751:Hepatitis E / Q000517:prevention & control* / Q000821:virology; D016752:Hepatitis E virus / Q000276:immunology*; D006801:Humans; D014761:Viral Hepatitis Vaccines
chemical_list: D015507:Drugs, Investigational; D014761:Viral Hepatitis Vaccines